Avastin with chemotherapy didn't increase heart risk, Roche says

12/17/2007 | Bloomberg1

The combination of tumor drug Avastin with anthracycline-based chemotherapy did not heighten the risk of heart problems in breast cancer patients who underwent surgery, Roche Holding said Saturday. The company intends to finish two late-stage studies on the drug before seeking approval for expanding its use to different types of tumors and different stages of breast cancer.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT